explore -WSS

explore

author：leisure time 2025-09-27 22:47:01 - browse：43156

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Dario to buy mental health app maker Twill in cash and stock deal

hotspot

WSS

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Medicare inequities exacerbate Puerto Rico’s health disparities

The untold story of TV’s first prescription drug ad

$1 billion proposal to grow Boston, Massachusetts biotech

STAT readers on older presidents, polypills, Medicare, and more

Medicare drug price negotiation continues, as pharma counteroffers

Wikipedia

explore

focus

Hollywood unions extend contract negotiations for actors

Fetal cell organoids grown from amniotic fluid, study finds

Cancer drug shortages should be causing more outrage

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Novavax promises a turnaround & Lilly roils the obesity market

Why palliative psychiatry is worth discussing

Activists slam private health insurers over coverage restrictions

$1 billion proposal to grow Boston, Massachusetts biotech

State Dept. review finds Biden bears some blame for Afghanistan failures

Change Healthcare: What is it, why does its cyberattack matter?

focus

Alabama IVF ruling threatens families facing fatal genetic disease

A new nitrogen execution bill also undermines medical licensing

Biden's 'march

A solution to the after

Microsoft's Peter Lee: Generative AI could help doctors be more human

Dario to buy mental health app maker Twill in cash and stock deal

knowledge

hotspot

focus

entertainment